SNY · NASDAQ · STOCK
Sanofi (SNY) Stock Analysis
$44.23
52W $40.89 – $52.68
62/100
$106.23B
23.3
0.28
Is SNY Bullish or Bearish?
Bullish.
Innellis AI committee rates Sanofi (SNY) Buy with a composite score of 62/100
, based on 4 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.09 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.91 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
62/100
Agreement
50%
Analysts
4
Conviction
Contested
Sector Rank
Top 42%
of 192 Healthcare peers
Growth Analyst
neutral
58
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score weakened from 65.0 to 61.9.
- Conviction changed from moderate to contested.
- Committee agreement fell notably from 67% to 50%.
- Bullish support removed: 3 signal(s) disappeared.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) abstained: Risk Analyst, Value Analyst.
Analyst-level changes:
- Growth Analyst: score 50->58 (+8).
- Risk Analyst abstained (was bullish at 80).
- Value Analyst abstained (was bullish at 70).
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
39.9
Neutral
MACD Histogram
-0.141
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$43.34
Resistance
$45.24
Bollinger %B
0.37
Inside Bands
Price vs Moving Averages
EMA 9
$44.58
Below
EMA 21
$44.51
Below
EMA 50
$44.21
Above
EMA 200
$45.62
Below
Fundamental Analysis
Valuation
89
Growth
67
Profitability
64
Financial Health
58
Cash Flow
70
Valuation
P/E Ratio
23.3×
P/B Ratio
1.32×
PEG Ratio
-0.35
Dividend Yield
10.93%
52W High
$52.68
52W Low
$40.89
Quality & Growth
ROE
1094.6%
ROA
616.1%
Gross Margin
7276.5%
Operating Margin
2058.1%
Revenue Growth YoY
—
Debt / Equity
0.34
AI Fundamental Assessment
P/E ratio of 23.3 (inexpensive relative to a 15-40x range); Price-to-book of 1.3x; PEG ratio of -0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.9%; Return on assets of 6.2%; Net margin of 8.1%; Gross margin of 72.8%; Current ratio of 0.99 (tight short-term liquidity); Debt-to-equity of 0.34; Free cash flow per share is positive (6.89); Most recent quarter beat estimates by 8.9%; 4 consecutive earnings beats; EPS growth decelerating (+22.9% -> +11.2% QoQ); Analyst estimates rising over recent quarters
Get the Full SNY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →